A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment
A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment
复制标题
一例伴有脑胶质瘤病的间变性星形细胞瘤儿科病例；
DOI：
10.1016/j.jocn.2020.10.009
复制
发表时间：
2020
影响因子：
2
通讯作者：
Ohnishi Hidenori
中科院分区：
文献类型：
--
作者：
Ninomiya Hiroshi;Ozeki Michio;Matsuzawa Yoriko;Nozawa Akifumi;Yasue Shiho;Kubota Kazuo;Endo Saori;Asano Takahiko;Taguchi Kohtaro;Ohe Naoyuki;Matsuo Masayuki;Iwama Toru;Ohnishi Hidenori
大脑胶质瘤病(GC)是一种罕见的弥漫性浸润性神经胶质肿瘤，预后不良。由于大多数患者在发病早期无法发现肿瘤，因此有望找到一种有用的诊断方法。我们比较了GC或胶质母细胞瘤患者和对照组的血清血管内皮生长因子(VEGF)-121水平。1例GC患者和胶质母细胞瘤患者的VEGF-121水平显著高于对照组。1例胃癌患者贝伐单抗治疗后血管内皮生长因子-121水平降低。因此，VEGF-121可能有助于GC的诊断、疾病监测和了解其病因。
Gliomatosis cerebri (GC) is a rare diffusely infiltrating glial neoplasm that carries a poor prognosis. Because tumors are undetectable in most patients at early-stage of the onset, a useful diagnostic method is expected. We compared serum vascular endothelial growth factor (VEGF)-121 levels in patients with GC or glioblastoma and controls. VEGF-121 levels were significantly higher in one patient with GC and patients with glioblastoma than in controls. VEGF-121 levels decreased in a patient with GC after bevacizumab-based therapy. Thus, VEGF-121 may be useful for diagnosing GC, its disease-monitoring and understanding its etiology.